三诺生物：公司生产经营正常，基本面稳健

Core Viewpoint - The company emphasizes that its stock price fluctuations in the secondary market are influenced by multiple factors, including company performance, macroeconomic conditions, industry environment, and market sentiment [1] Group 1: Company Operations and Performance - The company states that its production and operations are normal, and its fundamentals are stable, with no undisclosed matters [1] - The company has implemented a share buyback program, having repurchased 15.7553 million shares, which accounts for 2.81% of the total share capital, with nearly 300 million yuan invested as of February 13, 2026 [1] Group 2: Value Management and Strategic Initiatives - The company has established a "Market Value Management System" to enhance the quality of the listed company from a strategic perspective [1] - The company is focused on improving operational performance, optimizing investor return mechanisms, enhancing multi-dimensional communication, and strengthening transparency in information disclosure to align market value with intrinsic value [1] Group 3: Future Plans and Market Confidence - The company plans to continue strengthening its market value management efforts in line with its strategic development and business needs [1] - The company believes that the key to market confidence lies in the continuous enhancement of its core competitiveness, including innovation in diabetes management products, global strategy advancement, and steady improvement in operational quality [1]